Skip to main content

Clinical Trials › NCT04926818

Active, Not RecruitingPhase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsored by Novartis Pharmaceuticals

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
129
Target enrollment
6
U.S. states
Oct 2021
Start date
Mar 2031
Expected completion

Interventions / Treatments

FingolimodOfatumumabSiponimodFingolimod placeboSiponimod placeboOfatumumab placebo

Conditions studied

Multiple Sclerosis (MS)

Where this trial is running (6 sites)

Arkansas1 site
Little Rock
Los Angeles
Washington D.C.
Florida1 site
Tampa
Philadelphia
Wisconsin1 site
Milwaukee

MS centers in Arkansas

Compare treatment centers near a trial site by center type, providers and trials.

View Arkansas centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play